About 20 kinds of KRAS-mutant pancreatic cancer cell lines (listed in Supplementary Material, Table S1) were defined into either sensitive or resistant group, according to the median half-maximal inhibitory concentration (IC50) values of each MEKi in these cell lines. This evidence concerns the gene KRAS and pancreatic neoplasm.